PD-L1 (CPS) >= 10
About
Biomarker type: Protein expression
Marker: PD-L1
Unit: Combined Positive Score (CPS)
Equality: >=
Value: 10
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | PD-L1 (CPS) >= 10 | Adenocarcinoma of the Gastroesophageal Junction | Pembrolizumab | |
| FDA (2) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Pembrolizumab | |
| EMA (1) FDA (2) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Paclitaxel, Pembrolizumab | |
| EMA (1) FDA (2) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Bladder Urothelial Carcinoma | Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Cisplatin, Fluorouracil, Pembrolizumab | |
| EMA (1) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Nab-paclitaxel, Pembrolizumab |